NPM1 and Ewing sarcoma: Since NPM1 may be a potential therapeutic target for patients with ES, the NPM1 inhibitor was identified by reviewing the literature as NSC348884, which can bind specifically to NPM1 and specifically interfere with the formation of NPM1 oligomers (Qi et al., 2008).